Sugi Predict

Sugi Predict / Targets / NR2F2

NR2F2

COUP transcription factor 2 · P24468 · NR2F2 on Sugi Atlas →

25,408 patent compounds predicted against NR2F2, 16,771 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1033054 SCHEMBL1033054 0.45 4/20
SCHEMBL630436 SCHEMBL630436 0.45 4/20
SCHEMBL1027235 SCHEMBL1027235 0.43 4/20
Cycloheximide Cycloheximide (SCHEMBL26617) 1.00 3/20
Chlormidazole Chlormidazole (SCHEMBL148113) 1.00 3/20
Cycloheximide Cycloheximide (SCHEMBL674135) 1.00 3/20
Chlormidazole Chlormidazole (SCHEMBL364033) 0.97 3/20
SCHEMBL231295 SCHEMBL231295 0.79 3/20
SCHEMBL1104819 SCHEMBL1104819 0.62 3/20
SCHEMBL714379 SCHEMBL714379 0.61 3/20
SCHEMBL54157 SCHEMBL54157 0.58 3/20
SCHEMBL883724 SCHEMBL883724 0.57 3/20
SCHEMBL760728 SCHEMBL760728 0.57 3/20
SCHEMBL443290 SCHEMBL443290 0.55 3/20
Iodide Iodide (SCHEMBL198736) 0.54 3/20
Iodide Iodide (SCHEMBL636427) 0.54 3/20
SCHEMBL25004 SCHEMBL25004 0.50 3/20
SCHEMBL737002 SCHEMBL737002 0.50 3/20
SCHEMBL713649 SCHEMBL713649 0.47 3/20
SCHEMBL369182 SCHEMBL369182 0.47 3/20

Clinical trials — most relevant to NR2F2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanisms of Lipodystrophy in HIV-Infected Pateints PHASE4COMPLETED
Chronic Cold Acclimation Stimulates the Browning of Subcutaneous White Adipose in Patients With Type 2 Diabetes Mellitus PHASE4UNKNOWN
Preoperative Bexarotene Treatment for Cushing's Disease PHASE1/PHASE2UNKNOWN
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer. PHASE2UNKNOWN
A Study of Bezafibrate in Mitochondrial Myopathy PHASE2COMPLETED
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment PHASE2COMPLETED
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer PHASE2UNKNOWN
New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia PHASE2RECRUITING
Fibrates in Pediatric Cholestasis PHASE2COMPLETED
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy PHASE2ACTIVE_NOT_RECRUITING
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone. nanCOMPLETED
Study IL- 35 Level and Fibronectin Type Ⅲ Domain Containing Protein 5 \ Irsin (FNDC5 rs3480) Gene Variations in Chronic Hepatitis B. nanUNKNOWN
Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage Small Cell Lung Cancer During First-Line Chemoimmunotherapy nanNOT_YET_RECRUITING
Thermogenic Silencer Regulatory Factors in Humans nanACTIVE_NOT_RECRUITING
Nasturtium (Tropaeolum Majus L) Intake and Biochemical Parameters in Pre-diabetic Subjects in Bogota Colombia nanCOMPLETED
Long-term Outcome of GnRH Analogues Treatment of Children With Idiopathic Central Precocious Puberty nanUNKNOWN
Effect of Post Covid-19 Hypoxia on Placenta of Normal Pregnant Women: A Possible Role of Hypoxia Inducible Factor-1α. nanUNKNOWN
Steroid Treatment of Idiopathic Nephrotic Syndrome nanCOMPLETED
Clinical Study of Desuzumab in the Treatment of Knee Osteoarthritis nanRECRUITING
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders nanCOMPLETED
Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer nanUNKNOWN
RORC Genetic Polymorphism of Rheumatoid Arthritis nanCOMPLETED
Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women nanCOMPLETED
Evaluation of the Predictive Effect of Inflammatory Markers in MI Patients nanUNKNOWN
Genetic Determinants and Clinical Consequences of Early-onset Severe Obesity nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Gut Microbiome in Patients With Polycystic Ovary Syndrome nanUNKNOWN
Family Resilience Initiative Research Program nanUNKNOWN
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a NR2F2 binder may also engage these)

ProteinNameSimilarity
Q9TTR7 — 1.000 Q9TTR7 →
P43135 — 1.000 P43135 →
Q06725 — 1.000 Q06725 →
Q9TTR8 — 1.000 Q9TTR8 →
Q90733 — 1.000 Q90733 →
O09018 — 1.000 O09018 →
P10589 — 1.000 P10589 →
Q60632 — 1.000 Q60632 →
NR2E1 Nuclear receptor subfamily 2 group E member 1 1.000 landscape →
Q6PH18 — 0.999 Q6PH18 →
Q9YGL3 — 0.999 Q9YGL3 →
P28700 — 0.998 P28700 →
Q06726 — 0.998 Q06726 →
F1QLY4 — 0.997 F1QLY4 →
P50569 — 0.997 P50569 →
P33242 — 0.997 P33242 →
P51128 — 0.996 P51128 →
P51448 — 0.996 P51448 →
RXRA Retinoic acid receptor RXR-alpha 0.996 landscape →
P51129 — 0.996 P51129 →
Q90416 — 0.995 Q90416 →
Q64249 — 0.995 Q64249 →
Q7SYN5 — 0.995 Q7SYN5 →
NR1H2 Oxysterols receptor LXR-beta 0.994 landscape →
Q0VC20 — 0.994 Q0VC20 →
Q95L87 — 0.994 Q95L87 →
Q9GKL2 — 0.994 Q9GKL2 →
P06211 — 0.994 P06211 →
NR5A1 Steroidogenic factor 1 0.994 landscape →
P49117 — 0.994 P49117 →